Deutsch English Français

Contact

EP3960181

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3960181

EP3960181 - CHEMICALS AND METHODS TO PREVENT AND TREAT TGF-BETA MEDIATED ACTIVATION OF FIBROBLASTS TO REDUCE AND TREAT CANCER AND FIBROSIS [Right-click to bookmark this link]
Status	The application has been withdrawn Status updated on 01.12.2023 Database last updated on 30.09.2024
Former	Examination is in progress Status updated on 11.08.2023
Former	Request for examination was made Status updated on 28.01.2022
Most recent event Tooltip	01.12.2023	Withdrawal of application	published on 03.01.2024 [2024/01]
Applicant(s)	For all designated states Board of Supervisors of Louisiana State University and Agricultural and Mechanical College 3810 W. Lakeshore Drive Baton Rouge, LA 70808 / US
	[2022/09]
Inventor(s)	01 / CARDELLI, James Allen Shreveport, Louisiana 71115 / US
	02 / STEPHENS, Charles Albert Hot Springs, Arkansas, 71913 / US
	03 / GRAY, Alana Lea Shreveport, Louisiana, 71106 / US
	04 / COLEMAN, David Thomas Shreveport, Louisiana, 71106 / US
	[2022/09]
Representative(s)	J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB
	[N/P]
Former [2022/09]	Karakatsanis, Georgios Haft Karakatsanis Patentanwaltskanzlei Dietlindenstrasse 18 80802 München / DE
Application number, filing date	21198646.8	02.02.2017
	[2022/09]
Priority number, date	US201662290002P	02.02.2016 Original published format: US 201662290002 P
	[2022/09]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	EP3960181
	Date:	02.03.2022
	Language:	EN
	[2022/09]
	Type:	A3 Search report
	No.:	EP3960181
	Date:	01.06.2022
	Language:	EN
	[2022/22]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	04.05.2022
Classification	IPC:	A61K31/7048	[2022/09]
	CPC:	A61K31/7048 (EP,US); A61K31/4709 (EP,US); A61K31/704 (EP,US); A61K45/06 (EP,US); A61P35/00 (EP,US); A61P7/04 (EP,US); (+) A61K2300/00 (US); A61K31/045 (EP,US); A61K31/4412 (EP,US); A61K31/496 (EP,US) (-)
	C-Set:	A61K31/4709, A61K2300/00 (US,EP); A61K31/7048, A61K2300/00 (EP,US)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/09]
Title	German:	CHEMIKALIEN UND VERFAHREN ZUR VERHINDERUNG UND BEHANDLUNG VON TGF-BETA-VERMITTELTER AKTIVIERUNG VON FIBROBLASTEN ZUR REDUZIERUNG UND BEHANDLUNG VON KREBS UND FIBROSE	[2022/09]
	English:	CHEMICALS AND METHODS TO PREVENT AND TREAT TGF-BETA MEDIATED ACTIVATION OF FIBROBLASTS TO REDUCE AND TREAT CANCER AND FIBROSIS	[2022/09]
	French:	SUBSTANCES CHIMIQUES ET MÉTHODES POUR PRÉVENIR ET TRAITER L'ACTIVATION DES FIBROBLASTES MÉDIÉE PAR LE TGF-BÊTA, ET POUR COMBATTRE ET TRAITER LE CANCER ET LA FIBROSE	[2022/09]
Examination procedure	20.10.2021	Examination requested [2022/09]
	16.03.2023	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	11.05.2023	Amendment by applicant (claims and/or description)
	16.08.2023	Despatch of a communication from the examining division (Time limit: M04)
	29.11.2023	Application withdrawn by applicant [2024/01]
Parent application(s) Tooltip	EP17748126.4 / EP3411045
Request for further processing for:	The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application
	11.05.2023	Request for further processing filed
	11.05.2023	Full payment received (date of receipt of payment) Request granted
	22.05.2023	Decision despatched
	The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
	11.05.2023	Request for further processing filed
	11.05.2023	Full payment received (date of receipt of payment) Request granted
	22.05.2023	Decision despatched
Fees paid	Renewal fee
	20.10.2021	Renewal fee patent year 03
	20.10.2021	Renewal fee patent year 04
	20.10.2021	Renewal fee patent year 05
	25.02.2022	Renewal fee patent year 06
	27.02.2023	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[A] - MANNAERTS INGE ET AL, "The Hippo pathway effector YAP controls mouse hepatic stellate cell activation", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, (20150420), vol. 63, no. 3, doi:10.1016/J.JHEP.2015.04.011, ISSN 0168-8278, pages 679 - 688, XP029259374 [A] 1-18 * the whole document * * In particular: Title; Abstract; Materials and methods; Figures 1-7. * DOI: http://dx.doi.org/10.1016/j.jhep.2015.04.011
		[A] - WANG CHENG ET AL, "Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells", MOLECULAR MEDICINE REPORTS, GR, (20150126), vol. 11, no. 6, doi:10.3892/mmr.2015.3257, ISSN 1791-2997, pages 4101 - 4108, XP055871131 [A] 1-18 * the whole document * * In particular: Title; Abstract; Materials and methods. * DOI: http://dx.doi.org/10.3892/mmr.2015.3257
		[A] - FITAMANT JULIEN ET AL, "YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression", CELL REPORTS, US, (20150301), vol. 10, no. 10, doi:10.1016/j.celrep.2015.02.027, ISSN 2211-1247, pages 1692 - 1707, XP055871132 [A] 1-18 * the whole document * * In particular: Title; Summary; Figure 1; Discussion; Experimental procedures. * DOI: http://dx.doi.org/10.1016/j.celrep.2015.02.027
		[A] - Bai Haibo ET AL, "Evaluation of YAP as a therapeutic target in HCC and CCA.", (20150401), pages 1 - 2, URL: https://faseb.onlinelibrary.wiley.com/doi/10.1096/fasebj.29.1_supplement.45.4, (20211209), XP055871290 [A] 1-18 * the whole document *
		[A] - JIAO SHI ET AL, "A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer", CANCER CELL, CELL PRESS, US, (20140210), vol. 25, no. 2, doi:10.1016/J.CCR.2014.01.010, ISSN 1535-6108, pages 166 - 180, XP028610274 [A] 1-18 * the whole document * * In particular: Title; Summary; Discussion; Experimental procedures. * DOI: http://dx.doi.org/10.1016/j.ccr.2014.01.010
		[A] - BRODOWSKA KATARZYNA ET AL, "The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation", EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD, LONDON, (20140515), vol. 124, doi:10.1016/J.EXER.2014.04.011, ISSN 0014-4835, pages 67 - 73, XP028873521 [A] 1-18 * the whole document * * In particular: Title; Abstract; Materials and methods. * DOI: http://dx.doi.org/10.1016/j.exer.2014.04.011
		[X] - SILVIS MARK R. ET AL, "[alpha]-Catenin Is a Tumor Suppressor That Controls Cell Accumulation by Regulating the Localization and Activity of the Transcriptional Coactivator Yap1", SCIENCE SIGNALING, US, vol. 4, no. 174, doi:10.1126/scisignal.2001823, ISSN 1945-0877, (20110524), URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366274/pdf/nihms376579.pdf, XP055870843 [X] 1-18 * the whole document * * In particular: Title; Abstract; Discussion; Materials and methods; Figures 1-5. * DOI: http://dx.doi.org/10.1126/scisignal.2001823
	by applicant	- Encyclopedia of Pharmaceutical Technology, (20000000), vol. 5-6
		- HARRIS et al., Journal of Pharmaceutical Sciences, (19920000), vol. 81, no. 1, pages 1 - 10
		- "American Academy of Pediatrics: Alternative Routes of Drug Administration---Advantages and Disadvantages (Subject Review", Pediatrics, (19970000), vol. 100, no. 1, pages 143 - 152

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p